**Core Concept**
Antiplatelet drugs are a class of medications that inhibit platelet aggregation, thereby reducing the risk of thrombotic events. These drugs work by targeting various steps in the platelet activation cascade, including the release of granules, adhesion to the vascular wall, and aggregation with other platelets.

**Why the Correct Answer is Right**
Clopidogrel is a prodrug that requires metabolic activation to exert its antiplatelet effects. It is first converted to an intermediate metabolite, which is then further metabolized to its active form, clopidogrel-14-hydroxy derivative. This active metabolite irreversibly inhibits the P2Y12 receptor on platelet membranes, preventing adenosine diphosphate (ADP) from binding and thereby reducing platelet activation and aggregation. The prodrug status of clopidogrel allows for the formation of an active metabolite with potent antiplatelet effects.

**Why Each Wrong Option is Incorrect**
**Option A:** Aspirin is not a prodrug, as it directly inhibits the enzyme cyclooxygenase-1 (COX-1), which is responsible for the production of thromboxane A2, a potent platelet activator.

**Option B:** Dipyridamole is not a prodrug, as it directly inhibits platelet aggregation by inhibiting phosphodiesterase and blocking adenosine uptake, leading to increased levels of cyclic adenosine monophosphate (cAMP) in platelets.

**Option C:** Ticagrelor is not a prodrug, as it directly binds to and reversibly inhibits the P2Y12 receptor on platelet membranes, thereby preventing ADP from binding and reducing platelet activation and aggregation.

**Clinical Pearl / High-Yield Fact**
It's essential to note that the prodrug status of clopidogrel requires it to be metabolized by the liver enzyme cytochrome P450 2C19 (CYP2C19) to its active metabolite. Patients with reduced CYP2C19 activity may experience reduced antiplatelet effects and increased risk of cardiovascular events.

**Correct Answer:** C. Clopidogrel